04:13 PM EDT, 06/24/2025 (MT Newswires) -- Syndax Pharmaceuticals ( SNDX ) said Tuesday the US Food and Drug Administration has granted priority review for its supplemental new drug application for Revuforj to treat relapsed or refractory mutant NPM1 acute myeloid leukemia.

The supplemental new drug application is being reviewed under the regulator's real-time oncology review program and has been assigned a prescription drug user fee act, or PDUFA, target action date of Oct. 25, the company said.

The company's shares were rising 1.2% in recent after-hours activity.